The enhancement of siPLK1 penetration across BBB and its anti glioblastoma activity in vivo by magnet and transferrin co-modified nanoparticle.

In order to enhance the penetration of small interference RNA against the polo-like kinase I (siPLK1) across BBB to treat glioblastoma (GBM), transferrin (Tf) modified magnetic nanoparticle (Tf-PEG-PLL/MNP@siPLK1) was prepared. The in vitro experiments indicated that Tf-PEG-PLL/MNP@siPLK1 enhanced the cellular uptake of siPLK1, which resulted in an increase of gene silencing effect and cytotoxicity of Tf-PEG-PLL/MNP@siPLK1 on U87 cells. Besides, Tf-PEG-PLL/MNP@siPLK1 significantly inhibited the growth of U87 glioblastoma spheroids and markedly increased the BBB penetration efficiency of siPLK1 with the application of external magnetic field in in-vitro BBB model. The in vivo experiments indicated that siPLK1 selectively accumulated in the brain tissue, and markedly reduced tumor volume and prolonged the survival time of GBM-bearing mice after Tf-PEG-PLL/MNP@siPLK1 was injected to GBM-bearing mice via tail vein. The above data indicated that magnet and transferrin co-modified nanoparticle enhanced siPLK1 penetration across BBB and increased its anti GBM activity in vivo.

[1]  L. Kunz-Schughart,et al.  Multicellular tumor spheroids: an underestimated tool is catching up again. , 2010, Journal of biotechnology.

[2]  S. Futaki,et al.  Delivery of Macromolecules Using Arginine-Rich Cell-Penetrating Peptides: Ways to Overcome Endosomal Entrapment , 2009, The AAPS Journal.

[3]  Nishanth Krishnamurthy,et al.  Optical imaging and magnetic field targeting of magnetic nanoparticles in tumors. , 2010, ACS nano.

[4]  F. Pontén,et al.  Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas , 2015, Science Signaling.

[5]  Shijie Cao,et al.  Tumor cells and neovasculature dual targeting delivery for glioblastoma treatment. , 2014, Biomaterials.

[6]  M. Kenney,et al.  Transferrin receptor-targeted theranostic gold nanoparticles for photosensitizer delivery in brain tumors. , 2015, Nanoscale.

[7]  R. Stupp,et al.  Current concepts and management of glioblastoma , 2011, Annals of neurology.

[8]  Jianqing Gao,et al.  Characteristics of sequential targeting of brain glioma for transferrin-modified cisplatin liposome. , 2013, International journal of pharmaceutics.

[9]  Xiaoping Chen,et al.  Curcumin induces G2/M cell cycle arrest and apoptosis of head and neck squamous cell carcinoma in vitro and in vivo through ATM/Chk2/p53-dependent pathway. , 2017, Oncotarget.

[10]  P. Netti,et al.  Energetics of ligand-receptor binding affinity on endothelial cells: An in vitro model. , 2016, Colloids and surfaces. B, Biointerfaces.

[11]  N. Ahmad,et al.  Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics , 2016, Molecular Cancer Therapeutics.

[12]  Fabao Gao,et al.  Synergistic dual-ligand doxorubicin liposomes improve targeting and therapeutic efficacy of brain glioma in animals. , 2014, Molecular pharmaceutics.

[13]  T. Rana,et al.  Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer , 2015, Oncotarget.

[14]  Jenn-jong Young,et al.  Positively and negatively surface-charged chondroitin sulfate-trimethylchitosan nanoparticles as protein carriers. , 2016, Carbohydrate polymers.

[15]  Jun Chen,et al.  Enhancing Glioblastoma-Specific Penetration by Functionalization of Nanoparticles with an Iron-Mimic Peptide Targeting Transferrin/Transferrin Receptor Complex. , 2015, Molecular pharmaceutics.

[16]  Xun Li,et al.  Protein-bound P-cresol inhibits human umbilical vein endothelial cell proliferation by inducing cell cycle arrest at G0/G1. , 2017, American journal of translational research.

[17]  T. Mikkelsen,et al.  Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma , 2016, Science Translational Medicine.

[18]  V. Amani,et al.  Polo-like Kinase 1 as a potential therapeutic target in Diffuse Intrinsic Pontine Glioma , 2016, BMC Cancer.

[19]  David Westhead,et al.  Prediction of clinical outcome in glioblastoma using a biologically relevant nine‐microRNA signature , 2015, Molecular oncology.

[20]  Xin-guo Jiang,et al.  Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. , 2012, Biomaterials.

[21]  Mark E. Davis,et al.  Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor , 2013, Proceedings of the National Academy of Sciences.

[22]  Jun Wang,et al.  Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2+ Breast Cancer Growth and Metastasis , 2012, Science Translational Medicine.

[23]  Quanyin Hu,et al.  Glioma therapy using tumor homing and penetrating peptide-functionalized PEG-PLA nanoparticles loaded with paclitaxel. , 2013, Biomaterials.

[24]  Xiao-wei Zhu,et al.  Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma. , 2012, Acta histochemica.

[25]  L. Deangelis,et al.  Glioblastoma and other malignant gliomas: a clinical review. , 2013, JAMA.

[26]  Michael D. Taylor,et al.  Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells , 2012, BMC Cancer.

[27]  Q. Tao,et al.  Dickkopf-related protein 2 induces G0/G1 arrest and apoptosis through suppressing Wnt/β-catenin signaling and is frequently methylated in breast cancer , 2017, Oncotarget.

[28]  Triantafyllos Stylianopoulos,et al.  Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. , 2011, Annual review of chemical and biomolecular engineering.

[29]  Qiao Jiang,et al.  Enhanced gene delivery and siRNA silencing by gold nanoparticles coated with charge-reversal polyelectrolyte. , 2010, ACS nano.

[30]  Tao Wang,et al.  Challenges and opportunities for siRNA-based cancer treatment. , 2017, Cancer letters.

[31]  D. Hafler,et al.  Prospects of immune checkpoint modulators in the treatment of glioblastoma , 2015, Nature Reviews Neurology.

[32]  Xiaoling Fang,et al.  Nanoparticles functionalized with Pep-1 as potential glioma targeting delivery system via interleukin 13 receptor α2-mediated endocytosis. , 2014, Biomaterials.

[33]  Yu-Lan Hu,et al.  Glioma targeting and blood-brain barrier penetration by dual-targeting doxorubincin liposomes. , 2013, Biomaterials.

[34]  L. Ricci-Vitiani,et al.  Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo , 2014, Cell Death and Disease.

[35]  T. Nishioku,et al.  Paracellular barrier and tight junction protein expression in the immortalized brain endothelial cell lines bEND.3, bEND.5 and mouse brain endothelial cell 4. , 2013, Biological & pharmaceutical bulletin.